Invivyd Announces Positive 180-day Clinical Efficacy Data From CANOPY Phase 3 Trial Of Pemivibart

Biopharmaceutical company Invivyd, Inc. (IVVD) announced Tuesday positive 180-day clinical efficacy data from the companys ongoing CANOPY Phase 3 clinical trial of pemivibart, a half-life extended investigational monoclonal antibody (mAb), for the pre-exposure prophylaxis (PrEP) of COVID-19. The exploratory clinical efficacy data in Cohort B, a placebo-controlled cohort of all-comer immunocompetent individuals, showed a relative...

Read More

Morning session caught JCI slipping

JAKARTA – Jakarta Stock Price Composite Index (JCI) slipped to 7,565.78 right after the opening bell today (27/8) at 9.25 AM WIB. This trend is in contrast with the opening position at Monday (26/8), which arrived at 7,600. Monitoring the transaction during the morning session, JCI was seen fluctuating below the 7,600 level. However, it...

Read More